Pando Bioscience
ActiveGen-AI Designed Enzymes for Pharmaceutical Innovation
About
Pando is an AI-driven synthetic biology company revolutionizing enzyme engineering for the pharmaceutical industry. Our ultra-high-throughput screening platform screens 1000-fold more enzymes 75% faster and 80% cheaper than traditional methods. This empowers our generative AI to efficiently optimize enzymes across multiple properties, delivering high-performing, tailored enzymes that reduce costs and enhance efficiency.
Founders · 1
Will Cao is the co-founder and CEO of Pando Bioscience. During her Ph.D., Will changed her major from engineering machines to engineering bacteria (yes, making genetic modifications to bacteria, so they can produce things that they can't before). She has published first-author papers in Cell and Nature Biotechnology. In her spare time, she is a personal trainer and a kayak and scuba diving enthusiast.
Launch
Unlocking the full potential of enzymes to drive down costs and boost productivity in pharma
Pando presents an AI-driven synthetic biology platform for pharma enzyme engineering, combining AI-designed mutations with an ultra-high-throughput one-pot screening to design and test enzymes across multiple properties. It aims to reduce design-build-test-learn cycles to one month, helping pharma companies improve existing enzymes, discover new ones, and cut costs while boosting productivity.
From the original launch (Feb 2023) — may be outdated.
Related startups
Enzyme design models.
The AI-Native Operating System for Protein Engineering
